Newer approaches in treating chronic myelogenous leukemia
نویسندگان
چکیده
منابع مشابه
Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance
From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistan...
متن کاملFlow Cytometry in Chronic Myelogenous Leukemia Blast Crisis
Background: Chronic myelogenous leukemia (CML) is a myeloproliferative disorder due to BCR-ABL1 translocation. Patients showing transformation into blast crisis (BC) have poorer treatment response and prognosis. Methods: A retrospective study was conducted in the department of Pathology, Maulana Azad Medical College, New Delhi, India, over a time period of 5 years (2014-2019) to evaluate the ...
متن کاملFunction of Neutrophils in Different Phases of Chronic Myelogenous Leukemia
In chronic myelogenous leukemia (CML), the mature granulocytes originate from a stem cell line harboring an abnormal chromosome, therefore it is possible that metabolic-functional abnormalities occur in the morphologically mature cells. In the present study, the phagocytic activity including intracellular killing, nitro blue tetrazolium (NBT) reduction, and phagocytosis were studied in 37 CML p...
متن کاملNew approaches to the treatment of chronic myelogenous leukemia.
A number of therapeutic strategies have been introduced for the management and treatment of the benign phase of CML. Eighty years ago, radiation therapy was the only available treatment and splenic ir~ radiation was continued for a period in ex~ cess of 20 years when in 1924, Minot and colleagues published the now classic paper demonstrating that, although therapy could reduce morbidity of the ...
متن کاملChronic myelogenous leukemia.
The treatment recommendations for chronic myelogenous leukemia (CML) are evolving rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor, have become commercially available and non-myeloablative stem cell transplants continue to be refined. Clinicians and patients face a bewildering array of treatment options for CML. In this...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stem Cells
سال: 1993
ISSN: 1066-5099,1549-4918
DOI: 10.1002/stem.5530110906